News items A genetic patch to prevent hereditary deafness
3 March 2021

They can hear well up to about forty years old, but then suddenly deafness strikes people with DFNA9. The cells of the inner ear can no longer reverse the damage caused by a genetic defect in their DNA. Researchers at Radboud university medical center have now developed a “genetic patch” for this type of hereditary deafness, with which they can eliminate the problems in the hearing cells. Further research in animals and humans is needed to bring the genetic patch to the clinic as a therapy.

 

Hereditary deafness can manifest itself in different ways. Often the hereditary defect (mutation) immediately causes deafness from birth. Sometimes, as with DFNA9, you experience the initial problems in hearing after forty, fifty, sixty years. This has everything to do with the way DFNA9 mechanistically works. Every person gets half of his genes from his father and the other half from his mother. If you have two healthy copies of the DFNA9 gene, your inner ear works normal. If you receive a mutated copy of the gene from either your father or mother, deafness will develop later in life.

 

Protein spaghetti

Erik de Vrieze and Erwin van Wijk, both researchers at Hearing & Genes of the department of Ear, Nose and Throat, have conducted extensive research into the condition. De Vrieze: “We now know that you actually produce enough of the associated DFNA9 protein with just one healthy gene copy to be able to hear well for life. But there is a catch with this condition. The mutated protein is, in a way, disturbing the function of the healthy protein. It sticks to it, so that the healthy protein can also no longer do its job. This clumped protein spaghetti is constantly being removed by the cells of the inner ear, but after decades the clean-up service in these cells is reaching its limit and can no longer cope with these protein clumps. A threshold value is exceeded. As a result, the waste accumulates, the hearing cells start to function poorly and even die over time. After years of normal hearing, DFNA9 patients suddenly notice that their hearing is deteriorating, and sometimes deteriorating very quickly. Until at some point they will become deaf. ”

 

Enough time for treatment

The specific DFNA9 mutation seems to originate from a common ancestor in the Southern Netherlands, somewhere at the end of the Middle Ages. This can more or less be deduced from the spread of the fairly unique clinical manifestation, which is now estimated to occur in about 1500 people in the (southern) Netherlands and Belgium. Perhaps even more important than the origin of the disease is whether or not anything can be done about it. Van Wijk: “This condition has two favorable characteristics for therapy development. Firstly, it is a hereditary condition that only manifests itself after a few decades in life. In case an effective treatment will become available for this disease, a sufficiently large timeframe is available to apply it before the hearing loss really strikes. ”

 

Turning off mutant gene

The other point - developing an effective therapy - is a bit more complicated, but offers good starting points. Van Wijk: “The idea is that by specifically turning off the mutated gene copy you can prevent deafness. Without this mutated gene copy, no mutant protein will be produced and protein clumping will no longer take place. In addition, one healthy gene copy alone produces enough protein to maintain good hearing. ”

 

Genetic patch

De Vrieze and Van Wijk further developed this idea. Together with colleagues, they have now published the research results in the scientific journal Molecular Therapy - Nucleic Acids. “Genes, that reside on our DNA, provide the genetic code for the translation process into proteins,” says De Vrieze. “To get from a gene to a protein, you always need a translation process via so-called messenger RNA. And that is exactly the process we focused on. The unique DNA error in the DFNA9 gene is also reflected in the RNA. We developed a small piece of RNA that specifically binds to the messenger RNA derived from the mutated DFNA9 gene. As a result, the entire mutated messenger RNA is targeted for degradation. In this way, an essential link is lost and the mutant DFNA9 protein is no longer or hardly produced. The piece of RNA that we stick on the mutated DFNA9 messenger RNA is named an antisense oligonucleotide or "genetic patch".

 

Perspective

In recent years, De Vrieze and Van Wijk have not only developed this genetic patch, but also investigated its effect in cultured cells. Their current article is mainly describing these results, as the approach works in cultured cells. So there is a "proof of concept", as it is called in science. In short, the research shows that the approach works at the cellular level.

Arthur Robbesom of the "The Ninth of ..." DFNA9 Foundation is delighted with the study. “This offers a real perspective for about 1,500 people in the Netherlands and Belgium who are suffering from this condition. "The foundation is also closely involved in this research. Robbesom:" Now it is important to take the next necessary steps in the research as soon as possible. We will wholeheartedly support you.”

­­­­­­­­­­­­­­­­­­­­­­

Publication in Molecular Therapy - Nucleic Acids: Allele-specific antisense oligonucleotide therapy for dominantly inherited hearing impairment DFNA9 - Erik de Vrieze, Jolien Peijnenborg, Jorge Cañas Martin, Aniek Martens, Jaap Oostrik, Simone van der Heuvel, Kornelia Neveling, Ronald Pennings, Hannie Kremer, Erwin van Wijk.

Related news items


Hidden genetic defects contain real risks for serious diseases Genome test for consanguineous couples makes sense

19 March 2021 For the first time researchers from Hebrew University of Jerusalem, Radboudumc, Maastricht UMC+ and international colleagues have gained insight into the "hidden genetic defects" of the general European population. read more

Researchers grow most lifelike bone organoid to date Greatly increasing our understanding of bone formation and bone diseases

9 March 2021 Researchers from Radboudumc and Eindhoven University of Technology have interwoven various bone cells into an 'organoid' that can independently make new, hard bone tissue. It’s the most complete 3D model of bone formation to date. Peaked your interest? Read more! read more

A new consortium of the EU Innovative Medicines Initiative (IMI) aims to establish the biggest database of pathology images to accelerate the development of artificial intelligence in medicine

28 January 2021 To take AI development in pathology to the next level, a European consortium combining leading European research centres, hospitals as well as major pharmaceutical industries, is going to develop a repository for the sharing of pathology data. read more

Does the COVID-19 cytokine storm exist? Research may have an impact on the chances of success of a specific treatment

4 September 2020 Following the measurement of several important cytokines in patients with COVID-19 and various other severe diseases, researchers at Radboud university medical center now show that COVID-19 is not characterized by a cytokine storm. read more

Study on effect of BCG vaccine on coronavirus infection in the elderly

21 April 2020 Radboud university medical center and UMC Utrecht are working on a joint research project to discover whether the tuberculosis (BCG) vaccine reduces the risk of infection with the coronavirus in people aged 60 or older, or the severity of the symptoms in the event of infection. read more

Radboudumc researchers publish new insights into COVID-19 Consequences for treatment are now being examined internationally

10 April 2020 Researchers at the Radboud university medical center seem to have found an essential mechanism in the disease process of Covid-19, which has so far been overlooked. If the insight is correct, it probably has important consequences for the treatment of the disease. read more